Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | DAO | P14920 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | DDO | Q99489 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrazole SCHEMBL9442035 | 0.87 | FLT3 (0.33) | FLT3KDM4EDAOMAPTHPGD | |
| SCHEMBL367083 | 0.85 | FLT3 (0.46) | FLT3KDM4EDAOMAPTHPGD | |
| SCHEMBL18486436 | 0.82 | FLT3 (0.34) | FLT3KDM4EDAOMAPTHPGD | |
| SCHEMBL18486604 | 0.81 | KDM4E (0.33) | FLT3KDM4EDAOMAPTHPGD | |
| SCHEMBL1470509 | 0.81 | FLT3 (0.44) | FLT3KDM4EDAOMAPTHPGD | |
| SCHEMBL7848676 | 0.80 | FLT3 (0.39) | FLT3KDM4EDAOMAPTHPGD | |
| SCHEMBL5185736 | 0.80 | FLT3 (0.41) | FLT3NPC1CYP2A6KDRMEN1 | |
| SCHEMBL434362 | 0.80 | RAB9A (0.37) | FLT3KDM4EDAOMAPTHPGD | |
| SCHEMBL28281829 | 0.78 | GPR84 (0.43) | FLT3KDM4EDAOMAPTHPGD | |
| SCHEMBL29246527 | 0.76 | SLC22A6 (0.43) | FLT3GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080272-A1 | APTAMER-GATED NANOPARTICLES FOR LATERAL FLOW ASSAYS | Nanobiz Nanobiyoteknolojik Sistemler Egitim Bilisim Danismanlik Arge San.Tic. Ltd. Sti. (TR) | 2016-10-19 | — | — | EP | claimed |
| WO-2015088455-A1 | APTAMER-GATED NANOPARTICLES FOR LATERAL FLOW ASSAYS | NANOBIZ NANOBIYOTEKNOLOJIK SISTEMLER EGITIM BILISIM DANISMANLIK AR-GE SAN.TIC. LTD. STI. (TR) | 2015-06-18 | — | — | WO | claimed |
| EP-1724281-B1 | PATHOGENIC INFECTION DETECTION COMPOSITIONS AND METHODS | BIOKIT SA (ES) | 2013-02-13 | — | — | EP | disclosed |
| US-7700727-B2 | Compositions and kits for detecting pathogen infection | BIOKIT, S.A. (ES) | 2010-04-20 | — | — | US | disclosed |
| US-20060286119-A1 | Compositions and methods for treatment of chronic and infectious diseases | BIOKIT S.A. (ES) | 2006-12-21 | — | — | US | disclosed |
| US-20060275317-A1 | Vaccine compositions for prevention of chronic and infectious diseases | BIOKIT S.A. (ES) | 2006-12-07 | — | — | US | disclosed |
| US-20060269976-A1 | METHOD FOR REDUCING LYSOZYME ENZYMATIC ACTIVITY | BIOKIT S.A. (ES) | 2006-11-30 | — | — | US | disclosed |
| US-20060270835-A1 | Diagnosis and treatment of Alzheimer disease | BIOKIT S.A. (ES) | 2006-11-30 | — | — | US | disclosed |
| EP-1724281-A1 | PATHOGENIC INFECTION DETECTION COMPOSITIONS AND METHODS | Biokit S.A. (ES) | 2006-11-22 | — | — | EP | disclosed |
| US-20060063149-A1 | Compositions and methods for detecting pathogen infection | Patent Administrator | 2006-03-23 | — | — | US | disclosed |
| US-20050277181-A1 | Compositions and methods for detecting pathogen infection | BIOKIT S.A. (ES) | 2005-12-15 | — | — | US | disclosed |
| US-20030153019-A1 | Method and device for identifying a mycobacterium species responsible for a mycobacterial infection | RAPID MEDICAL DIAGNOSTICS, INC. | 2003-08-14 | — | — | US | disclosed |
| US-6416962-B1 | PROVIDING PREPARATION OF MYCOBACTERIUM SPECIES COMPRISING IMMUNO-CROSS-REACTIVE ANTIGEN COMPONENTS BOUND TO SOLID CARRIER, CONTACTING WITH TEST SAMPLE CONTAINING ANTIBODIES, DETECTING ANTIBODY-ANTIGEN BINDING TO IDENTIFY SPECIES | KREATECH BIOTECHNOLOGY B.V. (NL) | 2002-07-09 | — | — | US | disclosed |
| EP-0674766-B1 | METHOD AND DEVICE FOR IDENTIFYING A MYCOBACTERIUM SPECIES RESPONSIBLE FOR A MYCOBACTERIAL INFECTION | KREATECH BIOTECH BV (NL) | 2000-04-26 | — | — | EP | disclosed |
| US-5817473-A | FORMING ANTIGEN-ANTIBODY COMPLEX | KREATECH BIOTECHNOLOGY B.V. (NL) | 1998-10-06 | — | — | US | disclosed |
| EP-0674766-A1 | METHOD AND DEVICE FOR IDENTIFYING A MYCOBACTERIUM SPECIES RESPONSIBLE FOR A MYCOBACTERIAL INFECTION | KREATECH BIOTECHNOLOGY B.V. (NL) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994014069-A1 | METHOD AND DEVICE FOR IDENTIFYING A MYCOBACTERIUM SPECIES RESPONSIBLE FOR A MYCOBACTERIAL INFECTION | KREATECH BIOTECHNOLOGY B.V. (NL) | 1994-06-23 | — | — | WO | disclosed |
| US-5242820-A | Pathogenic mycoplasma | AMERICAN REGISTRY OF PATHOLOGY (US) | 1993-09-07 | — | — | US | disclosed |
| EP-0242264-A1 | Non-radioactive, single-stranded labelled probe, method for its production and method of detecting a target nucleotide sequence using this probe | INSTITUT PASTEUR (FR) | 1987-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063149-A1 | Compositions and methods for detecting pathogen infection | TREH, IL17A, TLL1 | FLT3 2157/4885KDM4E 4716/4885DAO 1645/4885 |
| US-20060275317-A1 | Vaccine compositions for prevention of chronic and infectious diseases | IL17A, TREH, MMP17 | FLT3 2540/4885KDM4E 4722/4885DAO 2735/4885 |
| US-20060269976-A1 | METHOD FOR REDUCING LYSOZYME ENZYMATIC ACTIVITY | TREH, PEPD, MMP17 | FLT3 3022/4885KDM4E 4359/4885DAO 733/4885 |
| US-20060286119-A1 | Compositions and methods for treatment of chronic and infectious diseases | IL17A, TREH, TLL1 | FLT3 2382/4885KDM4E 4813/4885DAO 1546/4885 |
| US-20050277181-A1 | Compositions and methods for detecting pathogen infection | TREH, IL17A, TLL1 | FLT3 2157/4885KDM4E 4716/4885DAO 1645/4885 |
| US-20060270835-A1 | Diagnosis and treatment of Alzheimer disease | PSEN1, APP, MMP17 | FLT3 3325/4885KDM4E 4652/4885DAO 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.